Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single Oral Dose Study Evaluating the Safety and Pharmacokinetics of BMN 349 in Homozygous for the Z Mutation of Alpha 1 Antitrypsin Gene (PiZZ) and Heterozygous for the Z Mutation (PiMZ/MASH)
NCT06738017 is registered in ClinicalTrials.gov with BioMarin Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Single Oral Dose Study Evaluating the Safety and Pharmacokinetics of BMN 349 in Homozygous for the Z Mutation of Alpha 1 Antitrypsin Gene (PiZZ) and Heterozygous for the Z Mutation (PiMZ/MASH)
- Lead sponsor
- BioMarin Pharmaceutical
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- February 21, 2025
- Completion date
- August 19, 2026
- Enrollment
- 6 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.